Giuseppe M. Peretti

Giuseppe M. Peretti

Auto-generated profile, based on publicly available information

Giuseppe M. Peretti

IRCCS Ospedale Galeazzi Sant'Ambrogio Milan Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MMMarcus Mumme
Marcus Mumme
AWAnke Wixmerten
Anke Wixmerten
AIAlan Ivković
Alan Ivković
GPGiuseppe M. Peretti
Giuseppe M. Peretti
TYTayfun Yilmaz
Tayfun Yilmaz
IMIvan Martin
Ivan Martin
Cartilage lesions do not heal spontaneously and predispose to osteoarthritis. Functional cartilage tissues, engineered using autologous chondrocytes, have a therapeutic advantage over conventional cellular therapies in preclinical studies. Here, we tested whether ex vivo maturation of engineered grafts for cartilage repair leads to improved patient benefit. Using autologous nasal chondrocytes (NCs), we tested whether implantation of in vitro–matured NC-tissue-engineered cartilage (N-TEC) versus undifferentiated NC-cell-activated matrices (N-CAM) in focal cartilage lesions would result in a superior clinical outcome. The prospective, randomized, parallel, open-label phase-2 trial ( ClinicalTrials.gov , NCT02673905) enrolled 108 patients in five hospitals from four countries. Patients ranging in age from 30 to 46 years with full-thickness knee cartilage defects (size, 2.7 to 6.0 square centimeters) were equally randomized and treated with N-TEC or N-CAM. The primary preregistered outcome was the overall Knee Injury Osteoarthritis Outcome Score (KOOS) at 24 months. N-TEC, which underwent a longer NC culture time, was phenotypically, structurally, and functionally more like hyaline cartilage than N-CAM. The overall KOOS increased with clinical relevance in both groups compared with preoperative values. KOOS was higher at 24 months for N-TEC [85; interquartile range (IQR), 74 to 91] than for N-CAM (79; IQR, 65 to 85). N-TEC, but not N-CAM, was similarly effective in patients with larger defects or revision surgery. Radiologically, N-TEC resulted in a superior composition of both repair tissue and surrounding cartilage, whereas structural scores were similar. This trial validates the clinical efficacy of NC-based grafts for articular cartilage repair and supports the clinical relevance of engineering mature tissues, even for patients with more challenging cartilage defects.

26 June 2025 in Blood
Verified
Journal Article
Open access
MVMatteo Claudio Da Vià
Matteo Claudio Da Vià
FLFrancesca Lazzaroni
Francesca Lazzaroni
AMAntonio Matera
Antonio Matera
AMAlessio Marella
Alessio Marella
AMAkihiro Maeda
Akihiro Maeda
NBNiccolò Bolli
Niccolò Bolli
Multiple myeloma (MM) is driven by clonal plasma cell (cPC)–intrinsic factors and changes in the tumor microenvironment (TME). To investigate whether residual polyclonal PCs (pPCs) are disrupted, single-cell (sc) RNA sequencing (scRNA-seq) and sc B-cell receptor analysis were applied in a cohort of 46 samples with PC dyscrasias and 21 healthy donors (HDs). Of 234 789 PCs, 64 432 were genotypically identified as pPCs with frequencies decreasing over different disease stages, from 23.66% in monoclonal gammopathy of undetermined significance to 3.23% in MMs (P = .00012). Both cPCs and pPCs had a comparable expression of typical lineage markers (ie, CD38 and CD138), whereas others were more variable (CD27 and ITGB7). Only cPCs overexpressed oncogenes (eg, CCND1/2 and NSD2), but CCND3 was often expressed in pPCs. B-cell maturation antigen was expressed on both pPCs and cPCs, whereas GPRC5D was mostly upregulated in cPCs with implications for on-target, off-tumor activity of targeted immunotherapies. In comparison with HDs, pPCs from patients showed upregulated autophagy and disrupted interaction with TME. Importantly, interferon-related pathways were significantly enriched in pPCs from patients vs HDs (adjusted P < .05) showing an inflamed phenotype affecting genotypically normal PCs. The function of pPCs was consequently affected and correlated with immunoparesis, driven by disrupted cellular interactions with TME. Leveraging our scRNA-seq data, we derived a “healthy PC signature” that could be applied to bulk transcriptomics from the CoMMpass data set and predicted significantly better progression-free survival and overall survival (log-rank P < .05 for both). Our findings show that genotypic sc identification of pPCs in PC dyscrasias has relevant pathogenic and clinical implications.

28 October 2025 in Knee Surgery, Sports Traumatology, Arthroscopy
Verified
Journal Article
Open access
LMLaura Mangiavini
Laura Mangiavini
NRNicolò Rossi
Nicolò Rossi
Riccardo GiorginoRiccardo Giorgino
Riccardo Giorgino
FBFrancesco Borelli
Francesco Borelli
ACAlessandra Colombini
Alessandra Colombini
LGLaura de Girolamo
Laura de Girolamo
Purpose: To evaluate the safety and efficacy of intra‐articular autologous transplantation of adipose‐derived connective tissue micrografts rich in stromal vascular fraction (CTM‐SVF), obtained using an enzyme‐free system (Hy‐Tissue® SVF) for knee osteoarthritis (OA). Methods: Thirty patients (mean age of 53.3 ± 6.4 years) with Kellgren–Lawrence grade I to III knee OA received a single intra‐articular injection of autologous CTM‐SVF prepared with the Hy‐Tissue SVF concentration system. Follow‐ups were set at 3‐, 6‐ and 12‐month postinjection. Outcome measures included knee injury and osteoarthritis outcome score (KOOS), pain relief (NRS‐11), quality of life (EQ‐5D index), magnetic resonance imaging (MRI) scans (whole‐organ magnetic resonance imaging score—WORMS, T2 mapping), OA serum biomarkers, safety and local tolerability. Results: One patient discontinued prematurely. KOOS improved significantly, with the highest mean score (68.7 ± 14.9) at 3 months and the majority of patients achieving a ≥ 9‐point increase from baseline. Results were maintained through 12 months. NRS‐11 and EQ‐5D also improved through 12 months, with more than 80% of patients meeting the NRS‐11 MCID at every timepoint. EQ‐VAS, however, showed only a modest responder rate (10%). MRI revealed improvements in T2 relaxation times, while OA serum biomarkers (evaluated at 3 months postinjection) indicated a significant decrease in Procollagen II N‐Terminal Propeptide levels. No device‐related adverse events (ADEs) were observed. The majority of adverse events (AEs) recorded during the study were mild and transient, none were classified as serious and resolved within a short period. Conclusions: Intra‐articular injection of autologous CTM‐SVF, obtained the Hy‐Tissue‐SVF system, proved to be effective and safe for managing knee OA symptoms and improving mobility, up to 12 months. Clinically significant pain relief and quality of life improvement were observed, particularly in the short term, with a gentle reduction of the scores over time. Larger controlled trials are required to confirm treatment durability. Level of Evidence: Level II.